Merck, Portola enter worldwide license pact to develop & commercialize betrixaban for cardiovascular disease

Merck & Co, Inc and Portola Pharmaceuticals, Inc have signed an exclusive global collaboration and license agreement for the development and commercialization of betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in phase-II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF).


Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying